Advenier C, Freslon J L
Br J Pharmacol. 1985 Oct;86(2):367-73. doi: 10.1111/j.1476-5381.1985.tb08905.x.
Small calibre airway reactivity to different contractile and relaxant agents was tested in vitro using small segments (about 1 mm long and 0.2 mm in internal diameter) of guinea-pig isolated intralobular bronchi. EC50 values of, and maximal contractile responses to contractile agents were as follows (mean +/- s.e.mean, n = 6): acetylcholine 13.6 +/- 2.6 microM and 1140 +/- 80 mg; histamine 5.2 +/- 0.7 microM and 1094 +/- 95 mg; 5-hydroxytryptamine (5-HT) 0.7 +/- 0.1 microM and 595 +/- 61 mg; prostaglandin F2 alpha (PGF2 alpha) 8.8 +/- 1.2 microM and 1100 +/- 88 mg; tetraethylammonium 2.9 +/- 0.3 mM and 1055 +/- 94 mg; KC1 14.6 +/- 0.5 mM and 965 +/- 81 mg. EC50 values of, and maximal relaxant responses to beta-adrenoceptor stimulants on preparations precontracted with acetylcholine (1.4 X 10(-4)M) were: isoprenaline 0.40 +/- 0.5 microM and 782 +/- 65 mg, n = 18; salbutamol 0.19 +/- 0.02 microM and 494 +/- 55 mg, n = 5; terbutaline 0.87 +/- 0.18 microM and 263 +/- 40 mg n = 5; fenoterol 0.06 +/- 0.02 microM and 722 +/- 47 mg, n = 5; adrenaline 0.71 +/- 0.13 microM and 653 +/- 62 mg, n = 5; noradrenaline 10.8 +/- 0.9 microM and 566 +/- 97 mg, n = 5. Differences in the maximal relaxant effects between the beta-adrenoceptor stimulants showed that the preparation utilized is a relevant model for assessment of the intrinsic activity of these drugs. 5 The high ratio (about 180) of the ECm for noradrenaline (beta-adrenoceptor agonist) to that for fenoterol (beta 2-adrenoceptor agonist), and the lack of effect of prenalterol (beta 1-adrenoceptor agonist) suggested that beta 2-adrenoceptors are preferentially involved in the relaxant activity of beta-adrenoceptor stimulants in this preparation.
采用豚鼠离体小叶内支气管小段(约1毫米长,内径0.2毫米)在体外测试小口径气道对不同收缩剂和舒张剂的反应性。收缩剂的半数有效浓度(EC50)值和最大收缩反应如下(平均值±标准误,n = 6):乙酰胆碱13.6±2.6微摩尔/升和1140±80毫克;组胺5.2±0.7微摩尔/升和1094±95毫克;5-羟色胺(5-HT)0.7±0.1微摩尔/升和595±61毫克;前列腺素F2α(PGF2α)8.8±1.2微摩尔/升和1100±88毫克;四乙铵2.9±0.3毫摩尔/升和1055±94毫克;氯化钾14.6±0.5毫摩尔/升和965±81毫克。在预先用乙酰胆碱(1.4×10⁻⁴M)预收缩的制剂上,β-肾上腺素能受体激动剂的半数有效浓度(EC50)值和最大舒张反应如下:异丙肾上腺素0.40±0.5微摩尔/升和782±65毫克,n = 18;沙丁胺醇0.19±0.02微摩尔/升和494±55毫克,n = 5;特布他林0.87±0.18微摩尔/升和263±40毫克,n = 5;非诺特罗0.06±0.02微摩尔/升和722±47毫克,n = 5;肾上腺素0.71±0.13微摩尔/升和653±62毫克,n = 5;去甲肾上腺素10.8±0.9微摩尔/升和566±97毫克,n = 5。β-肾上腺素能受体激动剂之间最大舒张作用的差异表明,所使用的制剂是评估这些药物内在活性的相关模型。5去甲肾上腺素(β-肾上腺素能受体激动剂)与非诺特罗(β2-肾上腺素能受体激动剂)的ECm高比值(约180)以及普瑞特罗(β1-肾上腺素能受体激动剂)无作用表明,β2-肾上腺素能受体在该制剂中β-肾上腺素能受体激动剂的舒张活性中起优先作用。